Filgrastim is a Recombinant Protein owned by Amgen, and is involved in 39 clinical trials, of which 32 were completed, and 7 are ongoing.

Filgrastim binds to the G-CSF receptor, which controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. It also stimulates the bone marrow for neutrophils production and decrease their maturation time. Filgrastim acts to raise the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, Filgrastim can accelerate neutrophil recovery, leading to a decrease in duration of the neutropenic phase.

The revenue for Filgrastim is expected to reach a total of $1.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Filgrastim NPV Report.

Filgrastim is currently owned by Amgen. Kyowa Kirin is the other company associated in development or marketing of Filgrastim.

Filgrastim Overview

Filgrastim (Neupogen, Gran, Granulokine, Grasin, Neupogen Novum) is recombinant-methionyl human granulocyte colony-stimulating factor (“G-CSF”). It is formulated as solution for intravenous and subcutaneous administration. It is indicated to reduce the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. It is employed for reducing the neutrophil time recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML and indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis in Blood Progenitor Cell Collection and Therapy. In addition to above mention indication it is used for chronic administration to reduce the incidence and duration of sequelae of neutropenia (eg‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia in patients with severe chronic Neutropenia. It stimulates the release of neutrophils from bone marrow storage pools and decrease their maturation time. It is also indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome). Neupogen is the first rHuG-CSF to be licensed to treat neutropenia in people with advanced HIV infection. Neupogen is also indicated for the treatment of acute radiation injury.

Filgrastim was under development for myelodysplastic syndrome.

Kyowa Kirin Overview

Kyowa Kirin, a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY352,246 million for the fiscal year ended December 2021 (FY2021), an increase of 10.6% over FY2020. In FY2021, the company’s operating margin was 17%, compared to an operating margin of 15.9% in FY2020. In FY2021, the company recorded a net margin of 14.9%, compared to a net margin of 14.8% in FY2020. The company reported revenues of JPY98,504 million for the third quarter ended September 2022, an increase of 1% over the previous quarter.

Quick View – Filgrastim

Report Segments
  • Innovator (NME)
Drug Name
  • Filgrastim
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Hematological Disorders
  • Oncology
  • Toxicology
Key Companies
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.